Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine added to Matrix therapy for methamphetamine use disorder
IRCT20090801002266N12Phase 3Completed
- Sponsor
- Esfarayen University of Medical Sciences
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in methamphetamine use disorder (MUD) comparing Buprenorphine + Matrix therapy with Placebo + Matrix therapy (2 arms). Primary endpoint: Reduction of relapse in methamphetamine-dependent patients following the use of buprenorphine. Started Aug 2019; status: completed.
02
Drugs
buprenorphine
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on IRCT20090801002266N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N12.